{"title": "Infectious Diseases Clinical Trials", "author": null, "url": "https://www.stjude.org/treatment/clinical-trials/infectious-diseases-clinical-trials.html", "hostname": "stjude.org", "description": "Infectious Diseases clinical trials at St. Jude Children's Research Hospital.", "sitename": "Stjuderesearch", "date": "2023-01-01", "cleaned_text": "St. Jude Clinical Trials - [COVID-19 Pediatric Vaccine Studies](https://www.stjude.org/treatment/clinical-trials/covid-19-pediatric-vaccine-studies.html) St. Jude is planning to participate in clinical trials to test COVID-19 prevention vaccines in healthy children. Find out more. - [REDIRECTED - COVID-19 Vaccine Study ENSEMBLE](https://www.stjude.org/treatment/clinical-trials/closed-to-accrual.html) St. Jude and UTHSC conducted trials in Memphis for a COVID prevention vaccine for adults. Read about the trial and its early results. [SENDAI:](https://www.stjude.org/treatment/clinical-trials/sendai-infectious-disease.html) [ A Phase I Study of Unmodified Live Intranasal Sendai Virus Vaccine in Children and Toddlers: Assessment of Safety and Immunogenicity ](https://www.stjude.org/treatment/clinical-trials/sendai-infectious-disease.html) Eligibility: - Child is greater than or equal to twelve (12) months and less than twenty-four (24) months. - Child has adequate blood, liver and kidney function. - Child has no history of lung disease, asthma, and hospitalization for respiratory illness, immunodeficiency, sickle cell disease, or any other serious underlying condition. [View Trial](https://www.stjude.org/treatment/clinical-trials/sendai-infectious-disease.html) Collaborative Clinical Trials [GS1269:](https://www.stjude.org/treatment/clinical-trials/gs1269-infectious-disease.html) [ Emtricitabine/Tenofovir Alafenamide (F/TAF) in HIV-1 Infected Children and Virologically Suppressed on a 2-NRTI-Containing Regimen](https://www.stjude.org/treatment/clinical-trials/gs1269-infectious-disease.html) Diseases Treated: Eligibility: - Participant is HIV-1 infected male or female aged six (6) to less than eight-teen (18) years of age at Baseline. - Participant is currently on a stable 2-NRTI (TDF containing) regimen that includes a protocol specified 3rd ARV agent for greater than or equal to six (6) consecutive months prior to screening. - Participant does not have an acquired immunodeficiency syndrome (AIDS) indicator condition with onset within thirty (30) days prior to screening. [View Trial](https://www.stjude.org/treatment/clinical-trials/gs1269-infectious-disease.html) [P1093:](https://www.stjude.org/treatment/clinical-trials/p1093-infectious-disease.html) [ Safety of and Immune Response to Dolutegravir in HIV-1 Infected Infants, Children, and Adolescents ](https://www.stjude.org/treatment/clinical-trials/p1093-infectious-disease.html) Diseases Treated: Eligibility: - At least 4 weeks old but younger than 18 years old - Confirmed HIV-1 infection - Current or past treatment with HIV medications (Children younger than 2 years old may be eligible even if they have not been treated with HIV medications.) [View Trial](https://www.stjude.org/treatment/clinical-trials/p1093-infectious-disease.html) [SENDAI:](https://www.stjude.org/treatment/clinical-trials/sendai-infectious-disease.html) [ A Phase I Study of Unmodified Live Intranasal Sendai Virus Vaccine in Children and Toddlers: Assessment of Safety and Immunogenicity ](https://www.stjude.org/treatment/clinical-trials/sendai-infectious-disease.html) Eligibility: - Child is greater than or equal to twelve (12) months and less than twenty-four (24) months. - Child has adequate blood, liver and kidney function. - Child has no history of lung disease, asthma, and hospitalization for respiratory illness, immunodeficiency, sickle cell disease, or any other serious "}